Special Issue

Clinical Application for Tissue Engineering

Message from the Guest Editors

Tissue engineering addresses the fabrication of functional three-dimensional structures that resemble the native organ. It is a transversal field that includes engineered cells, and engineered tissues, aiming to recreate, replace, and restore a whole or partial organ. As a dynamic field, tissue engineering is constantly evolving and integrating new areas of research such as nanotechnology and 3D-printing. Over 150 000 papers on tissue engineering were published in the last 30 years. However, few of the proposed solutions ended in real-world applications. Many projects suffer from technical limitations. The aim of this Special Issue is to provide more visibility to proof-of-concept studies in order to receive feedback from the scientific community. Targeting cutting-edge research in tissue engineering may help find new ways to tackle important health conditions in term of their diagnosis, treatment, and prevention. The Special Issue is open for submissions of basic to clinical research, or a multi-disciplinary approach, and reviews on the following topics: Cell sources:

Genetic tools;
Biomechanics;
Novel chemistries;
Self-assembly structures;
3D printing;
Nanotechnology.

Guest Editors

Dr. Francesco De Chiara Dr. Juanma Fernández-Costa Prof. Dr. Javier Ramón Azcón

Deadline for manuscript submissions

closed (15 November 2022)



an Open Access Journal by MDPI

Impact Factor 3.9 CiteScore 6.8 Indexed in PubMed



mdpi.com/si/100326

Biomedicines
Editorial Office
MDPI, Grosspeteranlage 5
4052 Basel, Switzerland
Tel: +41 61 683 77 34
biomedicines@mdpi.com

mdpi.com/journal/biomedicines





an Open Access Journal by MDPI

Impact Factor 3.9 CiteScore 6.8 Indexed in PubMed





About the Journal

Message from the Editor-in-Chief

Biomedicines (ISSN 2227-9059) is an open access iournal devoted to all aspects of research on human health and disease, the discovery and characterization of new therapeutic targets, therapeutic strategies, and research of naturally driven biomedicines, pharmaceuticals, and biopharmaceutical products. Topics include pathogenesis mechanisms of diseases, translational medical research, biomaterial in biomedical research, natural bioactive molecules, biologics, vaccines, gene therapies, cell-based therapies, targeted specific antibodies, recombinant therapeutic proteins, nanobiotechnology driven products, targeted therapy, bioimaging, biosensors, biomarkers, and biosimilars. The journal is open for publication of studies conducted at the basic science and preclinical research levels. We invite you to consider submitting your work to Biomedicines, be it original research, review articles, or developing Special Issues of current key topics.

Editor-in-Chief

Prof. Dr. Felipe Fregni

- Neuromodulation Center and Center for Clinical Research Learning, Spaulding Rehabilitation Hospital and Massachusetts General Hospital, Harvard Medical School, Boston, MA 02114, USA
- 2. Department of Epidemiology, Harvard T.H. Chan School of Public Health, Boston, MA 02115, USA

Author Benefits

High Visibility:

indexed within Scopus, SCIE (Web of Science), PubMed, PMC, CAPlus / SciFinder, and other databases.

Journal Rank:

JCR - Q1 (Pharmacology and Pharmacy) / CiteScore - Q1 (Medicine (miscellaneous))

Rapid Publication:

manuscripts are peer-reviewed and a first decision is provided to authors approximately 17 days after submission; acceptance to publication is undertaken in 2.9 days (median values for papers published in this journal in the first half of 2025).